Ingram Micro Cloud Publishes Cloud Technology: The State of MSPs Report Aimed at Guiding Reseller Success
29.3.2022 16:00:00 EEST | Business Wire | Press release
Ingram Micro Cloud, operator of the world’s largest cloud marketplace for the channel, announced on March 3rd the creation and release of its annual report examining prescient trends affecting Managed Service Providers (MSPs) and technology resellers. Cloud Technology: The State of MSPs Report analyzes key barriers and weaknesses that need to be addressed by MSPs in order to maximize on new and forecasted opportunities within the channel.
Cloud Technology: The State of MSPs Report is available for download here.
Drawing on the insights from over 600 MSPs acquired by Ingram Micro Cloud and global technology market research experts Vanson Bourne during an era of the greatest transformational shift in the history of the channel, the report provides revelations meant to benefit resellers and MSPs directly as they learn to navigate new business landscapes. Among its findings, the report recommends channel partners evolve to become strategic advisors to their customers; identify the most popular services provided by MSPs, including managed security and cloud services; and ensure they are in the best position to take advantage of the ever-increasing drive towards digitalization.
“From interviewing over 600 MSPs, it’s remarkable to see how 90% of service providers have seen client demand for managed services grow in the past 12 months, and close to two in three individuals surveyed say a lot of improvement is needed if their organization is going to be able to adapt to future opportunities,” said Craig Weir, executive director, global SaaS portfolio at Ingram Micro Cloud.
The report examines industry developments and MSP opportunities in the channel. These insights include:
- How MSPs are handling surging client demand and dramatic levels of growth.
- The top reasons why organizations look to outsource their IT operations.
- The most common managed services requested by clients.
- What MSPs believe to be the greatest opportunities in the marketplace right now.
- The challenges most likely to keep senior decision makers up at night.
Weir continues, “Today, I believe most MSPs are stuck in a digital impasse. Many MSPs are at an inflection point of knowing where they should go, but they just don’t know how to get there or even how to start. As we comb through the data, it’s clear to us some MSPs have solved this puzzle. They have enabled scale, they have found ways to accelerate growth, both of which have increased topline revenue; all while expanding recurring revenue streams to improve their bottom line. We see this today in what we call the Modern MSP.”
In closing, global managed services market will rise from $243 billion in 2021 to $557 billion in 2028, at a CAGR of 12.6%.1 Over the past 12 months, the top 3 services that generated the most revenue were: Cloud Services (SaaS, IaaS, PaaS) (22%), Managed Security (19%), and Internal IT Department (17%). All of this is indicative of the opportunity for MSPs to take notice and develop a stronger cloud business plan for the year and beyond. One thing is clear: it’s a great time to be an MSP.
For more information on the Cloud Technology: The State of MSPs Report and how Ingram Micro Cloud is helping partners leverage the research findings, visit here.
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers, and managed service providers by offering More as a Service. Detailed information is available at www.ingrammicrocloud.com.
Sources:
1. Managed Services Market Size, Share & COVID-19 Impact Analysis, By Services (Voice Service, Non-Voice Service, and IT Managed Service), By Function (Finance & Accounting (F & A), Marketing, Procurement, Supply Chain, Human Resource, and Information Technology (IT)), By End-user (Medical, Financial, Government, Audit & Consulting, Corporate, Telecom, and Insurance & Reinsurance), and Regional Forecast, 2021-2028,” Fortune Business Insights, August 2021. https://www.fortunebusinessinsights.com/managed-services-market-102430
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005020/en/
Contact information
Megan Binkley
Ingram Micro Cloud
Megan.Binkley@ingrammicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom